ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

ISTODAX® for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03742921

Enrollment

150

Registered

2018-11-15

Start date

2019-02-04

Completion date

2023-10-31

Last updated

2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, T-Cell, Peripheral

Keywords

Istodax, Survey, Relapsed or refractory, Peripheral T-Cell Lymphoma

Brief summary

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months

Interventions

DRUGIstodax

Istodax

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

\- Patients who have been diagnosed with relapsed or refractory PTCL who receive Istodax for the first time.

Exclusion criteria

N/A

Design outcomes

Primary

Measure	Time frame	Description
Adverse Events (AEs)	Up to approximately 5 years	Number of participants with adverse event

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026